Skip to main content
Top
Published in: Medical Oncology 1/2011

01-12-2011 | Original paper

Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population

Authors: Mahalakshmi Palani, Sabarinathan Devan, R. Arunkumar, A. J. Vanisree

Published in: Medical Oncology | Special Issue 1/2011

Login to get access

Abstract

Gliomas are the most common primary brain tumors in India. The main epigenetic modification in glioma is aberrant DNA methylation that is now renowned to be a common hallmark of brain tumors. This study was designed to determine the frequency of aberrant CpG island methylation in the promoter regions of p21 and p73 in different grades of glioma and to explore their respective chromosomal aberrations. Total of 160 patients with histologically confirmed grades of glioma (I, II, III, and IV) were included in the study. DNA samples from blood and brain tissues, including benign lesions were subjected to sodium bisulfite conversion and hypermethylation detection using methylation-specific PCR followed by RT–PCR. Western blotting was also carried out for p21 and its related protein, p53. A total of 124 of 160 glioma samples (77.5%) displayed CpG island hypermethylation of both p73, p21 genes associated with the loss of mRNA expression (P < 0.001) and the loss of protein expressions (p53 independent p21 expression). p73 gene showed increased methylation frequency in all grades, 40 of 60 (66%) glioblastomas and 16 of 30 (53.3%) anaplastic astrocytoma, 10 of 20(50%) oligodendrogliomas, 8 of 20 (40%) ependymoma, and low-grade glioma 6 of 20 (30%). The percentage of methylation significantly well correlated with the overall survival and also with chromosomal loss. Thus, the studied glioma patients among south Indians showed a high frequency of aberrant methylation with varied chromosomal signatures in different grades, playing a role in aggressiveness and characterization of a particular grade, the appreciation of which might help for designing a specific therapy.
Literature
1.
go back to reference Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetic joins genetics. Trends Genet. 2000;16:168–74.PubMedCrossRef Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetic joins genetics. Trends Genet. 2000;16:168–74.PubMedCrossRef
2.
go back to reference Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed
3.
go back to reference Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004;10:3441–54.PubMed Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004;10:3441–54.PubMed
4.
go back to reference Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K. Alterations in tumor suppressor gene p53 in human gliomas from Indian patients. J Bio Sci. 2002;27:673–8. Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K. Alterations in tumor suppressor gene p53 in human gliomas from Indian patients. J Bio Sci. 2002;27:673–8.
5.
go back to reference Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, epidemiology, and end results (SEER) data. J Neurosurg. 1991;88:1–10. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, epidemiology, and end results (SEER) data. J Neurosurg. 1991;88:1–10.
6.
go back to reference Lonso ME, Bello MJ, Lomas J, Gonzalez-Gomez P, Arjona D, De Campos JM, et al. Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol. 2001;19:609–12. Lonso ME, Bello MJ, Lomas J, Gonzalez-Gomez P, Arjona D, De Campos JM, et al. Absence of mutation of the p73 gene in astrocytic neoplasms. Int J Oncol. 2001;19:609–12.
7.
go back to reference Corn PG, Kuerbitz SJ, Van noesel MM, Esteller M, Compitello N, Baylin SB, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res. 1999;59:3352–6.PubMed Corn PG, Kuerbitz SJ, Van noesel MM, Esteller M, Compitello N, Baylin SB, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res. 1999;59:3352–6.PubMed
8.
go back to reference Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998;58:5061–5.PubMed Zhu J, Jiang J, Zhou W, Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 1998;58:5061–5.PubMed
9.
go back to reference Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. Neuro Oncol. 2002;59:143–9.CrossRef Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. Neuro Oncol. 2002;59:143–9.CrossRef
10.
go back to reference Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System World Health Organization Classification of Tumors. : IARC Press; 2000. Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System World Health Organization Classification of Tumors.  : IARC Press; 2000.
11.
go back to reference Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25.PubMed Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25.PubMed
12.
go back to reference Rey JA, Bello MJ, Jimenez-Lara A, Vaquero J, Kusak ME, de Campos JM, et al. Loss of heterozygosity for distal markers on 22q in human glioma. Int J Cancer. 1992;51:703–6.PubMedCrossRef Rey JA, Bello MJ, Jimenez-Lara A, Vaquero J, Kusak ME, de Campos JM, et al. Loss of heterozygosity for distal markers on 22q in human glioma. Int J Cancer. 1992;51:703–6.PubMedCrossRef
13.
go back to reference Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef
14.
go back to reference Banelli B, Casciano I, Romani M. Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000;19:4553–6.PubMedCrossRef Banelli B, Casciano I, Romani M. Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene. 2000;19:4553–6.PubMedCrossRef
15.
go back to reference Staalesen V, Leirvaag B, Lillehaug JR, Lonning PE. Genetic and epigenetic changes in p21 and p21B do not correlate with Resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res. 2004;15:3438–43.CrossRef Staalesen V, Leirvaag B, Lillehaug JR, Lonning PE. Genetic and epigenetic changes in p21 and p21B do not correlate with Resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res. 2004;15:3438–43.CrossRef
16.
go back to reference Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006;47:365–75.PubMedCrossRef Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006;47:365–75.PubMedCrossRef
17.
go back to reference Esteller M. Cancer epigenetic. DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39–49.PubMedCrossRef Esteller M. Cancer epigenetic. DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39–49.PubMedCrossRef
18.
go back to reference Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed Esteller M, Corn PG, Baylin SB, Herman JG. Gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed
19.
go back to reference Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2008;27:97–108.CrossRef Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene. 2008;27:97–108.CrossRef
20.
go back to reference Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, et al. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurgery. 2007;107:398–404.CrossRef Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, et al. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurgery. 2007;107:398–404.CrossRef
21.
go back to reference Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome19 in secondary glioblastomas. J Neuropathol Exp Neurol. 2000;59:539–43.PubMed Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome19 in secondary glioblastomas. J Neuropathol Exp Neurol. 2000;59:539–43.PubMed
22.
go back to reference Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Methylation of the p73gene in gliomas. Acta Neuropathol. 2002;104:357–62.PubMed Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Methylation of the p73gene in gliomas. Acta Neuropathol. 2002;104:357–62.PubMed
23.
go back to reference Bohnke A, Westphal F, Schmidt A, El-Awady R, Dahm-Daphi J. Role of p53 mutations, protein function and DNA damage for the radio sensitivity of human tumour cells. Int J Radiat Biol. 2004;21:362–409. Bohnke A, Westphal F, Schmidt A, El-Awady R, Dahm-Daphi J. Role of p53 mutations, protein function and DNA damage for the radio sensitivity of human tumour cells. Int J Radiat Biol. 2004;21:362–409.
24.
go back to reference Lxohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol. 2000;10:197–202.CrossRef Lxohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol. 2000;10:197–202.CrossRef
25.
go back to reference Schwab M, Praml C, Amler L. Genomic instability in 1p and human malignancies. Genes Chromosom Cancer. 1996;16:211–29.PubMedCrossRef Schwab M, Praml C, Amler L. Genomic instability in 1p and human malignancies. Genes Chromosom Cancer. 1996;16:211–29.PubMedCrossRef
26.
go back to reference Bello MJ, Leone PE, Nebreda P. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet. 1995;83:160–4.PubMedCrossRef Bello MJ, Leone PE, Nebreda P. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet. 1995;83:160–4.PubMedCrossRef
27.
go back to reference Von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544–58. Von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544–58.
28.
go back to reference Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, et al. Methylation profiles of thirty-four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004;4:65.PubMedCrossRef Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, et al. Methylation profiles of thirty-four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004;4:65.PubMedCrossRef
Metadata
Title
Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population
Authors
Mahalakshmi Palani
Sabarinathan Devan
R. Arunkumar
A. J. Vanisree
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9671-4

Other articles of this Special Issue 1/2011

Medical Oncology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.